Valuation: Haleos Labs Limited

Market Cap 4.54B 47.37M 41.57M 39.26M 35.78M 66.98M 67.45M 470M 182M 2.32B 178M 174M 7.45B P/E 2025
16.2x
P/E 2026 20.9x
Enterprise Value 5.63B 58.78M 51.58M 48.71M 44.39M 83.1M 83.7M 583M 226M 2.88B 221M 216M 9.25B EV / Sales 2025
1.19x
EV / Sales 2026 1.41x
Free-Float
25.03%
Yield 2025
0.14%
Yield 2026 0.13%
1 day-0.11%
1 week+0.28%
Current month+2.53%
1 month+0.06%
3 months+7.32%
6 months+20.11%
Current year+13.43%
1 week 1,481.5
Extreme 1481.5
1,554
1 month 1,437
Extreme 1437
1,554
Current year 1,091.1
Extreme 1091.1
1,774
1 year 1,091.1
Extreme 1091.1
1,774
3 years 472.05
Extreme 472.05
1,774
5 years 472.05
Extreme 472.05
1,774
10 years 128.45
Extreme 128.45
1,774
Manager TitleAgeSince
Chief Executive Officer 66 2017-05-31
Director of Finance/CFO - 2017-05-31
Chief Administrative Officer - 1995-07-06
Director TitleAgeSince
Chairman 66 -
Director/Board Member 69 2017-05-24
Director/Board Member - 2020-08-20
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+0.28%+30.68%+189.92% 47.37M
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.40%+0.69%+30.19%+62.62% 363.84B
Weighted average by Cap. +0.27%+1.32%+40.43%+68.22%

Financials

2025 2026
Net sales 3.45B 35.97M 31.56M 29.81M 27.16M 50.85M 51.21M 357M 138M 1.76B 135M 132M 5.66B 3.34B 34.83M 30.56M 28.86M 26.3M 49.24M 49.59M 345M 134M 1.71B 131M 128M 5.48B
Net income 201M 2.1M 1.84M 1.74M 1.58M 2.97M 2.99M 20.81M 8.06M 103M 7.88M 7.71M 330M 173M 1.81M 1.58M 1.5M 1.36M 2.55M 2.57M 17.91M 6.94M 88.44M 6.78M 6.64M 284M
Net Debt 859M 8.96M 7.87M 7.43M 6.77M 12.67M 12.76M 88.89M 34.43M 439M 33.65M 32.92M 1.41B 1.09B 11.41M 10.01M 9.45M 8.62M 16.13M 16.24M 113M 43.82M 559M 42.83M 41.9M 1.8B
Logo Haleos Labs Limited
Haleos Labs Limited is an India-based company. The Company is engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with all types of organic & inorganic chemicals, pharmaceuticals, active pharmaceutical ingredients (API) and intermediates. It caters to both domestic and international markets, with its product portfolio comprising established products such as Ranitidine hydrochloride (HCL) and Famotidine, along with other APIs and intermediates. Its products include Ranitidine HCl (Form-2) USP/EP/IP, Famotidine USP/EP/IP, Sildenafil Citrate USP/EP/IP, Allopurinol USP/EP/IP, Ropivacaine HCl USP/EP/IP, Dapsone USP/EP/BP, Sibutramine HCl USP, Itraconazole USP/EP, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP/IP, Tiagabine HCl USP, Albendazole USP/EP/IP, Fosaprepitant Dimeglumine, Hydroxyzine HCl USP/EP/IP, Trazodone HCl USP/EP/IP, and others.
Employees
611
Date Price Change Volume
26-09-25 ₹1,501.80 -0.11% 555
26-09-24 ₹1,503.40 -0.48% 1,264
26-09-23 ₹1,510.70 +0.71% 1,188
26-09-22 ₹1,500.00 +0.83% 339
26-09-21 ₹1,487.60 -0.67% 2,181
  1. Stock Market
  2. Stocks
  3. HALEOSLABS Stock